Key points
•
Proteasome inhibitors have become an important drug class in the treatment of multiple myeloma, and currently 3 have received regulatory approval.
•
In addition to its role in myeloma cells, the proteasome plays a critical role in the myocardium, particularly in the context of cardiac stress.
•
The growing awareness of the cardiovascular toxicity of proteasome inhibitors is emerging following the phase 3 trials and the transition into real-world practice.